跳至主要内容
临床试验/EUCTR2006-002614-36-IT
EUCTR2006-002614-36-IT进行中(未招募)不适用

Multicentre, controlled, randomised, open-label, cross-over clinical study of the efficacy and tolerability of L-thyroxine T4 soft capsules, in comparison to L-thyroxine tablets, in thyroidectomised patients. - ND

IBSA0 个研究点目标入组 300 人开始时间: 2007年1月30日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
IBSA
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Out-patients of both sexes; between 18 and 75 years of age; total thyroidectomy for any reasons, with consequent state of biological hypothyroidism; undetectable thyroglobulin levels 1 g/L or ng/mL and undetectable thyroglobulin autoantibodies by a sensitive immunoassay at screening; replacement/TSH suppressive therapy with T4 tablets stable for at least 3 months; adequate metabolic control; availability and possibility of taking part in the study; reasonable assumption of understanding the study and of reliability; written informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • seriously compromised cardiac heart failure , hepatic, renal, respiratory functions; serious metabolic e.g. uncompensated diabetes mellitus , organs e.g. cirrhosis of the liver , endocrine or systemic diseases excluding the basic pathology ; neoplastic diseases active or in remission for less than 5 years excluding the basic pathology ; terminal condition; parenteral or assisted enteral feeding; serious psychiatric problems whether or not being treated or compromising the patient s reliability; non-therapeutic use of psychotropic substances; alcoholism; pregnancy, current or planned within the next 12 months; breast-feeding; hypersensitivity to the ingredients of the preparations; concomitant medications interfering with the study evaluations; participation in other clinical studies in the two months preceding screening; presumption of poor reliability/co-operation.

研究者

发起方
IBSA

相似试验

进行中(未招募)
1 期
Multicentre, controlled, randomised, open-label, cross-over clinical study of the efficacy and tolerability of L-thyroxine (T4) soft capsules, in comparison to L-thyroxine tablets, in thyroidectomised patients.Post- operation hypothyroidismMedDRA version: 9.1Level: LLTClassification code 10021117Term: Hypothyroidism postoperative
EUCTR2006-002614-36-FRIBSA, Institut Biochimique SA205
进行中(未招募)
1 期
Multicentre, randomised, controlled, open-label, study comparing the efficacy and safety of slow repeated intravenous infusions of 2 doses of Doxorubicin Transdrug™ (DT) (20 mg/m² or 30 mg/m²) to those of best standard of care (BSC) in patients with advanced hepatocellular carcinoma (HCC) after failure or intolerance to sorafenib - ReLive Study - ReLive
EUCTR2011-002843-92-ITBioAlliance Pharma397
进行中(未招募)
1 期
Study comparing the efficacy and safety of doxorubicin Transdrug™ administered intravenously to the best available treatment in patient suffering from liver cancer after treatment with sorafenib.
EUCTR2011-002843-92-HUOnxeo390
进行中(未招募)
1 期
Study comparing the efficacy and safety of doxorubicin Transdrug™ administered intravenously to the best available treatment in patient suffering from liver cancer after treatment with sorafenib.Advanced Hepatocellular Carcinoma (HCC)
EUCTR2011-002843-92-ATOnxeo390
进行中(未招募)
1 期
Study comparing the efficacy and safety of doxorubicin TransdrugTM administered intravenously to the best available treatment in patient suffering from liver cancer after treatment with sorafenib.Advanced hepacellular carcinoma (HCC)
EUCTR2011-002843-92-ESBioAlliance Pharma390